tradingkey.logo
tradingkey.logo
Search

Genfit SA

GNFT
Add to Watchlist
4.850USD
0.0000.00%
Close 07/02, 13:00ETQuotes delayed by 15 min
741.27MMarket Cap
--P/E TTM

More Details of Genfit SA Company

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA Info

Ticker SymbolGNFT
Company nameGenfit SA
IPO dateDec 19, 2006
CEOPrigent (Pascal)
Number of employees180
Security typeDepository Receipt
Fiscal year-endDec 19
AddressParc Eurasante 885 avenue Eugene Avinee
CityLOOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code59120
Phone33320164000
Websitehttps://www.genfit.fr/
Ticker SymbolGNFT
IPO dateDec 19, 2006
CEOPrigent (Pascal)

Company Executives of Genfit SA

Name
Name/Position
Position
Shareholding
Change
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

FAQs

Who are the top five shareholders of Genfit SA?

The top five shareholders of Genfit SA are: Mr. Jean-Francois Mouney

How many institutions hold shares of Genfit SA (GNFT)?

As of 2026Q1, 16 institutions hold shares of Genfit SA, with a combined market value of approximately 22.36K, accounting for 0.04% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -215235.00.